• Delia Marina Podea ―Vasile Goldis‖ Western University of Arad, Faculty of Medicine
  • Raluca Ioana Palici County Clinical Emergency Hospital of Arad


Mental health, elderly, mild cognitive impairment


Currently, those aged 65 years or above comprise about 6% of the world's population. The reasons for this explosion in the older population in the world in general, and in the develop world in particular are many, and are not just a result of increasing life expectancy. Other factors including the declining fertility rate, declining child mortality, education and economic development play a big part. The ageing population of the world presents major challenges for society and for health services. Mental health issues are extremely important, as mental disorders, notably dementia and depression, are common in old age. Mental ill-health can profoundly affect the quality of life of elderly people and has a significant impact upon the use of health and social services.
Taking into account the fact that the mild cognitive impairment is considered as a prodromal phase of dementia, it is important to identify it early and to start the primary prevention. The primary prevention refers to the specific treatment of cognitive features and to changes of the lifestyle. The compliance and the lifestyle can stop the progression of the disease. Early detection and the treatment of mild cognitive impairment can maintain the elderly at a maximum level of functionality as much as possible. It is therefore important to improve quality of life the elderly, so that to maintain healthy and functional as long as possible, to prevent their admission to hospitals or homes-hospitals.


Bart Sheehan, Salman Karim, Alistair Burns, Old age psychiatry, Oxford Specialist Handbooks in Psychiatry.

Agronim E.M., Alzheimer Disease and other dementias, Second Edition, Lippincott Wiliams&Wilkins, 2004.

International Psychogeriatrics, Special Issue – focus on Mild Cognitive Impairment, Cambridge University Press, Vol. 20, Number 1, February 2008.

Belleville, S., Lepage, E., Bhere, L., Chertrkow, H. and Gauthier, S. Measures of executive functions and working memory in older persons with mild cognitive impairment. Paper presented at the ninth Cognitive Aging Conference , Atlanta, GA, USA, 2002.

Myron F. Weiner, MD, Anne M. Lipton, MD, PhD, Textbook of Alzheimer Disease and Other Dementias.

Tassman A., Kay J., Lieberman J.A., Psychiatry, Second Edition, Cam treatments, Wiley.

Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a arandomised trial, JAMA, 2008 sep 3;300(9): 1027-1037.

Nikolaos Scarmeas, MD; Yaakov Stern, PhD; Richard Mayeux, MD; Jennifer J. Manly, PhD; Nicole Schupf, PhD; Jose A. Luchsinger, MD. Mediterranean Diet and Mild Cognitive Impairment, Arch Neurol. 2009;66(2):216-225.

Moniz-Cook E., Manthorpe J., Early psycosocial Intervention in Dementia, Evidence -Based Practice, Jessica Kingsley publishers, London and Philadelphia, 2009.

Spar J.E., Asenath La rue, Clinical Manual of Geriatric Psychiatry, American Psychiatric Publishing Inc., 2006.

Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007 Apr 18;(2):CD003120.

M, Erensto C, Thomas RG, et al. A controlled trial of selegiline , alpha-tocopherol, or both as treatment for Alzheimer‟s disease. The Alzheimer‟s Disease Cooperative Study. N Engl J Med.1997; 336: 1216-1222.

Rogers SL, Farlow MR, DoodyRS, Mohs R, Friedhoff LT. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer‟s disease. Donepezil Study Group. Neurology.1998;50:136-145.

Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer‟s disease: international randomised controlled trial. BMJ. 1999;318: 633-638.

Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer‟s disease: multicenter randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321: 1445-1449.

Alan M. Mellow, Geriatric Psychiatry: Review of Psychiatry.

Burns J.M., Morris J.C., Mild Cognitive Impairment and Early Alzheimer's Disease detection and diagnosis, Wiley, 2008.

Petersen RC, Smith GE, Waring SC. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56.

Petersen RC. Aging, mild cognitive impairment, and Alzheimer's disease. Neurol Clin 2000.

Dubois B., Feldman H.H., Jacova C. et al., Revising the definition of Alzheimer disease: a new lexicon, Lancet Neurol, 2010 Nov; 9(11):1118-1127.

Karakaya T, Fusser F, Schroder J et al., Pharmacological treatment of mild cognitive impairment as a prodromal syndrome of Alzheimer disease, Current Neuropharmacology. 2013 Jan; 11(1): 102–108

Moniz-Cook E, Manthorpe J (2009): Early Psychosocial Intervention in Dementia, Evidence-Based Practice, London and Philadelphia: Jessica Kingsley publishers 23. Galbete JL, Martin TR, Peressini E et al., Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 2000;348:307–313.

Simons M, Schwärzler F, Lütjohann D, Von Bergmann K et al., Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 2002;52:346–350. 25. Gómez-Isla T, Blesa R, Boada M, Clarimón J et al., A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMICI study. Alzheimer Dis. Assoc. Disord. 2008;22:21–19.




Most read articles by the same author(s)